AC IMMUNE SA (ACIU) Stock
NMQ · ACIU
2.63
Fundamentals
Market cap
$261.49M
Price / Earnings ratio
-5.1x
Price / Sales ratio
12.6x
Price / Book ratio
6.3x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About AC IMMUNE SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
SectorHealthcare
IndustryBiotechnology
Employees90
CEODr. Martin Zugel M.D., Ph.D.
IPO DateSep 23, 2016
HeadquartersLausanne, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher Roberts | CFO & VP of Finance | 1990 |
| Mr. Piergiorgio Donati | Chief Operating Officer | 1971 |
| Dr. Martin Zugel M.D., Ph.D. | Interim CEO & Chairman of the Board | 1963 |
| Dr. Gary Anthony Waanders Ph.D. | Senior VP of Investor Relations & Corporate Communications | 1964 |
| Dr. Matthias Maurer Ph.D. | Senior VP & General Counsel | 1982 |
| Dr. Oliver Sol M.D. | VP & Head of Clinical Development | 1968 |
| Dr. Julien Rongere Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | 1978 |
| Mr. Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence | 1964 |
| Dr. Günther Staffler Ph.D. | Executive Vice President of Development | 1969 |
| Dr. Francesca Capotosti | Senior Vice President of Research | — |
Fundamentals
Valuation
Market cap$261.49M
Price-to-sales ratio12.62
Price-to-book value6.28
Price-earnings ratio-5.10
Return on Equity-124.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.53
Income Statement
Average volume180,054
EBITDA$-86.86M
1 year high (52w)$4.00
1 year low (52w)$2.10
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



